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Abstract
Aims: To prospectively explore the association between non-high-density lipoprotein cholesterol (non-HDLC) and the
risks of stroke and its subtypes.
Methods: A total of 95,916 participants (18-98 years old; 76,354 men and 19,562 women) from a Chinese urban
community who were free of myocardial infarction and stroke at baseline time point (2006-2007) were eligible and
enrolled in the study. The serum non-HDLC levels of participants were determined by subtracting the high-density
lipoprotein cholesterol (HDLC) from total serum cholesterol. The primary outcome was the first occurrence of stroke,
which was diagnosed according to the World Health Organization criteria and classified into three subtypes: ischemic
stroke, intracerebral hemorrhage, or subarachnoid hemorrhage. The Cox proportional hazards models were used to
estimate risk of stroke and its subtypes.
Results: During the four-year follow-up, we identified 1614 stroke events (1,156 ischemic, 416 intracerebral
hemorrhagic and 42 subarachnoid hemorrhagic). Statistical analyses showed that hazard ratios (HR) (95%
Confidence Interval: CI) of serum Non-HDLC level for total and subtypes of stroke were: 1.08 (1.03-1.12) (total), 1.10
(1.05-1.16) (ischemic), 1.03 (0.96-1.10) (intracerebral hemorrhage) and 0.83 (0.66-1.05) (subarachnoid hemorrhage).
HR for non-HDLC refers to the increase per each 20 mg/dl. For total and ischemic stroke, the risks were significantly
higher in the fourth and fifth quintiles of non-HDLC concentrations compared to the first quintile after adjusting the
confounding factors (total stroke: 4th quintile HR=1.33 (1.12-1.59); 5th quintile HR = 1.36 (1.15-1.62); ischemic stroke:
4th quintile HR =1.34 (1.09-1.66); 5th quintile HR = 1.53 (1.24-1.88)).
Conclusions: Our data suggest that serum non-HDLC level is an independent risk factor for total and ischemic
stroke, and that higher serum non-HDLC concentrations are associated with increased risks for total stroke and
ischemic stroke, but not for intracerebral and subarachnoid hemorrhage.
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Introduction
Stroke is a major healthcare problem and a serious economi
c burden to society. In China, stroke is the leading cause of
death and long-term disability. Currently, more than 7,000,000
individuals suffer from stroke, and there are 2,000,000
individuals with newly diagnosed stroke each year [1,2].
Atherosclerosis and lipoprotein disorders have been
indicated as critical pathological changes during the
development of stroke [3]. Non-high-density lipoprotein
cholesterol (non-HDLC) is composed of several atherogenic
lipoproteins, including very-low-density lipoprotein (VLDL), low-
density lipoprotein (LDL), intermediate-density lipoprotein (IDL),
and lipoprotein (a). The US National Cholesterol Education
Program Adult Treatment Panel guideline III (NCEP-ATP III)
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has set goals for non-HDLC after the achievement of LDL
cholesterol (LDLC) goals in patients with elevated triglycerides
[3]. Recent studies have demonstrated that the predictive value
of non-HDLC in coronary heart disease (CHD) incidence is
similar to or better than LDLC [4–7]. With respect to stroke,
studies have been conducted to investigate the relationship
between non-HDLC and risk of stroke. Studies reported that
elevated serum TC or LDLC concentrations were associated
with increased risk of ischemic stroke but reduced risk for
intracerebral hemorrhage (ICH) stroke [8]. In contrast, in the
other two Japanese cohort studies no association between
non-HDLC and stroke was found [9,10]. A cohort study on
Chinese population recently found that the level of non-HDLC
was a predictive factor for ischemic stroke [11]. In summary,
previous reports regarding the relationship between non-HDLC
and the risk of stroke remain highly controversial. Here we
reported a large prospective cohort study with Chinese
population to test if serum non-HDLC is associated with risks of
different subtypes of stroke.
Materials and Methods
Study design and population
The Kailuan study was a prospective cohort based in Kailuan
community in Tangshan city, which is a large and littoral
modern city located in the southeast of Beijing. The detail
information about Kailuan Study has been described previously
[12–14]. From June 2006 to October 2007, all the 155,418
residents (including the retired) in the community were invited
to participate. The inclusion criteria were: (1) aged 18 years or
older; and (2) provided a written informed consent. In total,
101,510 (65.31%) participants (81,110 men and 20,400
women, aged 18-98 years old) were recruited into the Kailuan
study. The participants enrolled in our study were mainly the
mining employees of the Kailuan group with a significantly
higher male to female ratio (4:1) than the general Chinese
population. All the participants received questionnaire
assessments, clinical and laboratory examinations, which were
conducted by medical professionals in the 11 designated
hospitals in Kailuan community. In this study, the following
participants were excluded: 3,669 participants who had history
of myocardial infarction (MI) and/or stroke at baseline, 1,214
participants who did not receive non-HDLC measurement (or
whose serum non-HDLC level was not measured), and 711
participants who had taken lipid-lowering agents. Eventually, a
total of 76,354 men and 19,562 women were included (Figure
1) in the analyses. The study was performed according to the
guidelines of Helsinki Declaration and was approved by the
Ethics Committees of Kailuan General Hospital, and Beijing
Tiantan Hospital.
Measurement of Non-HDLC level at baseline
Blood samples were collected from an antecubital vein of
participants in the next morning after overnight fast (>8 hours)
and then transferred into vacuum tubes containing EDTA
(Ethylene Diamine Tetraacetic Acid). All the blood samples
were processed and analyzed using an auto-analyzer (Hitachi
747; Hitachi, Tokyo, Japan) at the central laboratory of the
Kailuan General Hospital.
Level of total cholesterol (TC) in serum was measured using
endpoint test method. HDLC and LDLC were measured with
direct test method. Triglyceride (TG) was measured by GPO
method (inter-assay coefficient of variation < 10%; Mind
Bioengineering Co. Ltd, Shanghai, China). Non-HDLC level
was determined by subtracting serum HDLC from serum TC.
Assessment of potential covariates at baseline
Information on demographic variables (e.g., age, sex, and
education) was collected via questionnaires. The education
level was categorized as “college or higher”, “middle school”, or
“illiteracy or primary school”.
Information on smoking and physical activity was also
collected via questionnaires. Weight and height were measured
during the interview and body mass index (BMI) was calculated
as weight (kg)/height (m)2. BMI was classified as ideal if it was
<25 kg/m2. Systolic Blood pressure (SBP) and Diastolic Blood
pressure (DBP) were measured twice in the seated position
using a mercury sphygmomanometer. The average of two
readings was used in the analyses.
Assessment of incident stroke
The participants were followed up by face-to-face interviews
at every two-year routine medical examination until December
31, 2010 or to the event of interest or death. The follow-ups
were performed by hospital physicians, research physicians,
and research nurses who were blinded to the baseline data.
The outcome information for the participants without face-to-
face follow-up was obtained by referring to death certificates
from provincial vital statistics offices, discharge summaries
from the 11 hospitals, and medical records from medical
insurance.
The primary outcome was the first occurrence of stroke;
either the first nonfatal stroke event or a stroke death. A
nonfatal stroke was defined as a focal neurological deficit of
sudden onset and vascular mechanism that lasted >24 hours.
Stroke was diagnosed according to the World Health
Organization (WHO) criteria [15] combined with brain
computed tomography (CT) or magnetic resonance (MR)
confirmation, and classified into three main types: ischemic
stroke, intracerebral hemorrhage, or subarachnoid
hemorrhage. The criteria were consistent across all
participating hospitals. All stroke records were reviewed by two
independent stroke specialists. If instances of disagreement in
a single case, the final evaluation was made by the event
adjudication committee. All the stroke outcomes were validated
by the Data Safety Monitoring Board and Arbitration Committee
for Clinical Outcomes.
Statistical analysis
The participants were classified into 5 groups according to
quintiles of serum non-HDLC level. In addition, medians and
proportions of potential risk factors for stroke among these 5
groups were calculated. Continuous variables between groups
were compared by Variance analysis, while categorical
variables were analyzed by Chi-Square test. The raw and
Cholesterol and Stroke
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adjusted hazard ratios (HRs) with 95% confidence intervals
(CIs) were calculated from the Cox proportional hazards model.
There were 11 hospitals participating in the current study.
Thus, the cox proportional hazard model with a sandwich
covariance matrix as a random effect was used to account for
the potential effects due to different treatment centers. Other
potential confounders included age, gender, BMI, hypertension,
diabetes, smoking and drinking status (‘never’, ‘former’,
‘occasional’, or ‘daily’), physical activity status (‘very active’,
‘moderately active’, or ‘inactive’), HDLC, and triglyceride. A
trend test was used to examine the relationship between
different quartile levels of serum non-HDLC and the risk of
stroke. Outcome assessors and statisticians were independent
and were blinded to the participants’ baseline information. All
statistical analyses were performed with the SAS software,
version 9.2 (SAS Institute, Cary, NC, USA). All CIs were
estimated at the 95% level and signiﬁcance was set at a P
value of <0.05 (2-sided).
Figure 1.  Flowchart of the study.  
doi: 10.1371/journal.pone.0074634.g001
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Results
Baseline non-HDLC levels and characteristics of other
variables for study participants
In our study, all participants were followed up to the event of
interest or death through multiple ways. For participants who
took the every two-year routine medical examination, they were
followed up by face-to-face interviews by hospital physicians
and nurses. For those without face-to-face interviews, their
follow up information was obtained by checking death
certificates from provincial vital statistics offices, discharge
summaries from the 11 designated hospitals, or medical
records from medical insurance companies. However, we were
did not collect the information in this study regarding the
proportion of the cohort followed up by face-to-face or by
records only.
During the four-year follow-up, we identified a total of 1,614
stroke cases, including 1,156 ischemic, 416 intracerebral
hemorrhage, and 42 subarachnoid hemorrhage. Table 1
summarizes baseline participants’ characteristics according to
quintile categories of serum non-HDLC concentration. The
median value of non-HDLC from the lowest quintile to the
highest quintile at baseline was 87.0 mg, 112.5 mg, 130.3 mg,
149.3 mg, and 179.8 mg, respectively. We found that there
were significant differences in age, BMI, SBP, DBP,
concentrations of serum TC and HDLC, and triglyceride
concentration among groups. These variables, with an
exception of HDLC, tended to be increased in the higher non-
HDLC quintile groups, whereas only the serum HDLC levels
were lower in the higher quintile groups. Compared to the lower
non-HDLC quintile groups, there were more males, daily
smokers, daily drinkers and a larger proportion of participants
with inactive physical activity, hypertension, and diabetes in the
higher non-HDLC quintile groups.
Serum non-HDLC is an independent risk factor for total
and ischemic stroke
Multivariate analysis in Table 2 showed that serum non-
HDLC level was an independent risk factor for both total stroke
and ischemic stroke (for total stroke, HR=1.08, 95% CI,
1.03-1.12; for ischemic stroke, HR=1.10, 95% CI, 1.05-1.16)
(Table 2). The HR for non-HDLC refers to the increase per
each 20 mg/dl. Other factors including age, male, daily
smoking, BMI, hypertension, and diabetes mellitus were
independent risk factors for ischemic stroke, and the
associated HRs with 95% CIs were 1.06 (1.05-1.06), 1.76
(1.41-2.19), 1.59 (1.35-1.88), 1.03 (1.015-1.05), 2.10
(1.82-2.42), 1.79 (1.54-2.09), respectively. Occasional or daily
drinking is a protective factor for ischemic stroke with an HR of
0.65 (0.53-0.81) and 0.76 (0.63-0.92), respectively (Table 2).
Serum non-HDLC level was not an independent risk factor for
intracerebral hemorrhage stroke (HR=0.83, 95% CI, 0.66-1.05)
and subarachnoid hemorrhage (HR=1.03, 95% CI, 0.96-1.10)
(Table 2).
Higher serum non-HDLC is associated with increased
risks of total and ischemic stroke independent of other
potential confounding factors
As demonstrated in Table 3, serum non-HDLC levels were
associated linearly with incidence of total stroke (P trend <
0.01) and ischemic stroke (P trend < 0.01). These associations
were not changed after adjusting for potentially confounding
factors (Table 3). Compared to the first quintile, the incidences
of total stroke and ischemic stroke were significantly higher in
the fourth (total stroke: HR=1.33, 95% CI, 1.12-1.59; ischemic
stroke, HR=1.343, 95% CI, 1.09-1.66) and fifth quintiles (total
Table 1. Characteristics of Participants According to
Quintile Groups of Non-High-Density Lipoprotein
Cholesterol at baseline.
 Quintile* P value
 Q1 Q2 Q3 Q4 Q5  
Median non-HDLC, mg/dl 87.0 112.5 130.3 149.3 179.8 <0.01
Number of persons 19180 19230 19083 19235 19188 <0.01
Male,% 79.3 78.0 79.6 80.3 80.9 <0.01
Age, year 51.0 51.2 51.3 51.8 52.3 <0.01
Smoking,%       
never 63.7 64.1 62.1 57.3 55.3 <0.01
former 5.2 4.9 4.9 5.7 6.0 <0.01
occasional 3.8 3.3 3.6 3.7 3.5 <0.01
daily 27.3 27.7 29.4 33.4 35.4 <0.01
Drinking,%       
never 61.4 62.5 61.4 56.0 54.6 <0.01
former 3.6 3.1 3.3 3.7 3.7 <0.01
occasional 19.3 19.1 18.9 20.7 19.4 <0.01
daily 15.8 15.3 16.4 19.6 22.4 <0.01
Physical activity,%       
inactive 7.3 7.6 8.2 9.7 10.5 <0.01
moderate 79.7 78.5 78.1 74.2 71.2 <0.01
very 12.9 13.9 13.7 16.1 18.3 <0.01
Education,%       
illiteracy or primary school 10.5 9.0 9.1 10.2 11.8 <0.01
middle school 80.5 83.5 84.6 83.3 82.6 <0.01
≥college 9.0 7.5 6.2 6.5 5.6 <0.01
Hypertension,% 40.6 40.8 43.4 44.7 49.5 <0.01
Diabetes,% 7.3 7.3 8.0 9.8 13.5 <0.01
Body mass index, kg/m2 24.1 24.5 24.8 25.2 25.5 <0.01
Systolic blood pressure,
mmHg 125.0 126.7 129.3 130.0 130.0 <0.01
Diastolic blood pressure,
mmHg 80.0 80.0 80.0 80.7 82.0 <0.01
Fasting blood glucose, mg/dl 89.6 90.5 91.9 93.5 95.9 <0.01
Total cholesterol, mg/dl 146.2 170.5 189.1 206.9 239.8 <0.01
HDLC, mg/dl 61.5 58.4 58.0 56.5 56.8 <0.01
Triglyceride, mg/dl 95.7 78.0 79.6 80.3 80.9 <0.01
Abbreviation: HDLC = high-density lipoprotein cholesterol.
*. Q1 represents the lowest fifth of the data (1-20%), Q2 represents the second
lowest fifth (21-40%), Q3 represents the middle fifth (41-60%), Q4 represents the
second highest fifth (61-80%), and Q5 represents the highest fifth (81-100%).
doi: 10.1371/journal.pone.0074634.t001
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stroke: HR=1.36, 95% CI, 1.15-1.62; ischemic stroke:
HR=1.53, 95% CI, 1.24-1.88) after adjusting for the
confounding factors. We did not find significant associations
between serum non-HDLC cholesterol levels and incidences of
intracerebral hemorrhage (P trend = 0.45) and subarachnoid
hemorrhage (P trend = 0.12) (Table 3).
In order to determine the effect of potential confounding
factors on the significant association between serum non-
Table 2. Risk Factors for Ischemic Stroke and Total Stroke.
 Adjusted HR*(95% CI)
Variable Total stroke ICH stroke Ischemic stroke SAH stroke
Male 1.52(1.28-1.81)†
1.22
(0.89-1.68)
1.76 (1.41-2.19)
†
0.54
(0.22-1.29)
Age‡ 1.05(1.05-1.06)†
1.04
(1.03-1.05)†
1.06 (1.05-1.06)
†
1.03
(0.99-1.06)
Smoking     
never 1(reference) 1(reference) 1(reference) 1(reference)
former 1.07(0.85-1.34)
1.46
(0.96-2.24) 0.95 (0.72-1.25)
0.96
(0.25-3.71)
occasional 1.39(1.02-1.90)†
1.47
(0.83-2.60) 1.40 (0.96-2.04)
0.60
(0.08-4.75)
daily 1.43(1.24-1.65)†
1.09
(0.81-1.47)
1.59 (1.35-1.88)
†
0.88
(0.36-2.14)
Drinking     
never 1(reference) 1(reference) 1(reference) 1(reference)
former 1.10(0.87-1.40)
0.84
(0.49-1.45) 1.16 (0.88-1.52)
1.90
(0.38-9.51)
occasional 0.72(0.60-0.86)†
0.81
(0.57-1.15)
0.65 (0.53-0.81)
†
2.09
(0.82-5.31)
daily 0.81(0.69-0.95)†
0.92
(0.66-1.28)
0.76 (0.63-0.92)
†
1.99
(0.71-5.57)
Physical
activity     
inactive 1(reference) 1(reference) 1(reference) 1(reference)
moderate 1.20(0.97-1.48)
1.27
(0.82-1.97) 1.16(0.91-1.49
1.48
(0.44-4.99)
very 0.88(0.70-1.12)
0.99
(0.61-1.64) 0.86 (0.65-1.13)
0.61
(0.15-2.88)
Hypertension 2.23(1.97-2.51)†
2.66
(2.10-3.38)†
2.10 (1.82-2.42)
†
1.87
(0.93-3.77)
Diabetes 1.57(1.37-1.80)†
1.06
(0.78-1.44)
1.79 (1.54-2.09)
†
0.95
(0.33-2.72)
Body mass
index
1.03
(1.01-1.04)†
1.01
(0.98-1.04)
1.03 (1.01-1.05)
†
1.08
(0.99-1.17)
Non-HDLC§ 1.08(1.03-1.12)†
1.03
(0.96-1.10)
1.10 (1.05-1.16)
†
0.83
(0.66-1.05)
HRs, hazard ratios; CI, confidence interval; ICH, intracerebral hemorrhage; SAH,
subarachnoid hemorrhage; Non-HDLC, non-high-density lipoprotein cholesterol
*. Adjusted potential confounders included age, sex, body mass index,
hypertension, diabetes, triglycerides, high-density lipoprotein cholesterol, smoking
status, drinking status, physical activity status; stratified by hospitals.
†. P<0.05
‡. the HR for age refers to the increase per year.
§. the HR for non-HDLC refers to the increase per each 20 mg/dl.
doi: 10.1371/journal.pone.0074634.t002
HDLC level and stroke incidences shown in Table 4, we further
performed analysis of the data stratified by different risk
factors. As shown in Table 4, gender, age, hypertension,
diabetes, smoking and BMI did not affect the association
between serum non-HDLC concentration and ischemic stroke
(P value for each interaction was
0.73,0.96,0.47,0.77,0.12,0.84, respectively), strongly
suggesting that non-HDLC level in serum is an independent
risk factor for incidence of ischemic stroke.
Discussion
The results of the present large prospective study, based on
a community population in China with greater than 96,000
participants, suggested that serum non-HDLC level is an
independent risk factor for stroke and one of its subtypes,
ischemic stroke. Our data identified a positive association
between serum non-HDLC level and the incidences of total
stroke and ischemic stroke.
Although the positive association of serum non-HDLC level
with the risk of coronary heart diseases has been well
documented [5,16,17],, information about the relationship
between serum non-HDLC and stroke remains limited and
controversial. A study by Ren et al. reported that higher serum
non-HDLC levels were associated with the increased risk for
ischemic stroke in a mid-aged Chinese population [11]. In
contrast, some prospective studies, independently conducted
in Japanese adult population did not find a significant
association between serum non-HDLC and stroke incidences.
Specifically, the Suita study by Okamura et al. indicated that
the incidence of cerebral infarction stroke was not associated
with serum non-HDLC level in either men or women [9]; The
Japan Arteriosclerosis Longitudinal Study – Existing Cohorts
Combine (JALS-ECC) study reported that serum non-HDLC
concentration was not significantly associated with the risk of
any of the stroke subtypes [10]. In the present report, we
conducted a community-based, large prospective study by
enrolling close to 1000,000 participants, and showed that the
serum non-HDLC level is an independent risk factor for total
and ischemic stroke and significantly associated with their
incidences, which was not affected by potential confounding
factors such as gender, age, sex and BMI. Our results are
consistent with the study by Ren et al. and substantially extend
their observations. Possible reasons to explain the
discrepancies between our study and the two studies on
Japanese population may be that ischemic stroke is a
heterogeneous syndrome in which many different pathways
can lead to the same clinical presentations. The classical
pathogenesis for ischemic stroke have been defined as large-
artery atherosclerotic infarction that may be caused by
extracranial or intracranial artery atherosclerotic infarction,
embolism from a cardiac source, small-vessel disease,
dissection, hypercoagulable states, sickle cell disease, and
other unidentified causes [18]. Serum TC or LDLC
concentrations were associated with atherothrombotic
infarction, but not with lacunar infarction that was usually
caused by non-atherosclerotic disease of small diameter
penetrating arteries [19,20]. The positive association between
Cholesterol and Stroke
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serum non-HDLC concentration and ischemic stroke in
Chinese populations could partially be explained by the high
frequency of atherothrombotic infarction. As some studies have
indicated, there are more lacunar strokes than
atherothrombotic infarctions Japanese adult population
compared to Chinese or American adults [21–25]. Furthermore,
non-HDLC is composed of several atherogenic lipoproteins,
including VLDL, LDL, IDL and lipoprotein (a), and each of them
Table 3. Hazard Ratios (HRs) of Stroke According to Quintile Categories of Non-High-Density Lipoprotein Cholesterol.
 Quintile (median non-high-density lipoprotein cholesterol, mg/dl) P trend
 Q1(87.0) Q2(112.5) Q3(130.3) Q4(149.3) Q5(179.8)  
Total stroke       
Incidence case (%) 261 (1.36) 298 (1.55) 297 (1.56) 361 (1.88) 397 (2.07)  
Crude HR (95% CI) 1 1.15 (0.97-1.35) 1.17 (0.99-1.38) 1.42 (1.21-1.67) 1.60 (1.37-1.88) <0.01
Adjusted HR*(95% CI) 1 1.19 (0.99-1.42) 1.16 (0.97-1.39) 1.33 (1.12-1.59) 1.36 (1.15-1.62) <0.01
Ischemic stroke       
Incidence case (%) 179 (0.93) 206 (1.07) 208 (1.09) 256 (1.33) 307 (1.69)  
Crude HR (95% CI) 1 1.15 (0.94-1.40) 1.19 (0.97-1.45) 1.50 (1.20-1.77) 1.81 (1.50-2.18) <0.01
Adjusted HR*(95% CI) 1 1.17 (0.95-1.45) 1.20 (0.97-1.48) 1.34 (1.09-1.66) 1.53 (1.24-1.88) <0.01
Intracerebral hemorrhage stroke       
Incidence case (%) 72 (0.38) 80 (0.42) 86 (0.45) 94 (0.49) 84 (0.44)  
Crude HR (95% CI) 1 1.14 (0.83-1.57) 1.24 (0.91-1.71) 1.38 (1.01-1.89) 1.26 (0.91-1.74) 0.08
Adjusted HR*(95% CI) 1 1.21 (0.87-1.69) 1.19 (0.85-1.66) 1.36 (0.98-1.89) 1.18 (0.78-1.55) 0.45
Subarachnoid hemorrhage stroke       
Incidence case (%) 16 (0.05) 12 (0.06) 3 (0.02) 11 (0.06) 6 (0.03)  
Crude HR (95% CI) 1 1.07 (0.56-2.49) 0.27 (0.07-0.97) 0.88 (0.37-2.11) 0.48 (0.17-1.34) 0.14
Adjusted HR*(95% CI) 1 1.27 (0.51-3.15) 0.30 (0.08-1.15) 0.93 (0.36-2.39) 0.46 (0.15-1.39) 0.12
*. Adjusted potential confounders included age, sex, body mass index, hypertension, diabetes, triglycerides, high-density lipoprotein cholesterol, smoking status, drinking
status, physical activity status; stratified by hospitals.
doi: 10.1371/journal.pone.0074634.t003
Table 4. Adjusted Hazard ratios* with 95% confidence intervals of Ischemic Stroke According to Quintile Categories of Non-
High-Density Lipoprotein Cholesterol Levels, Stratified by Selected Risk Factors.
 Quintile (median non-high-density lipoprotein cholesterol, mg/dl) P trend P for interaction
 Q1(87.0) Q2(112.5) Q3(130.3) Q4(149.3) Q5(179.8)   
Gender        
Female 1 1.02 (0.50-2.09) 0.83 (0.39-1.75) 1.48 (0.77-2.86) 1.46 (0.76-2.81) 0.09 0.73
Male 1 1.16 (0.93-1.46) 1.22 (0.97-1.52) 1.32 (1.06-1.64) 1.54 (1.25-1.91) <0.01 0.73
Age, years        
<60 1 1.25 (0.90-1.73) 1.26 (0.91-1.73) 1.43 (1.05-1.96) 1.65 (1.22-2.24) <0.01 0.96
≥60 1 1.07 (0.80-1.42) 1.11 (0.83-1.48) 1.24 (0.94-1.65) 1.40 (1.06-1.85) <0.01 0.96
Hypertension        
Yes 1 1.02 (0.79-1.31) 1.05 (0.82-1.35) 1.15 (0.90-1.47) 1.34 (1.06-1.70) <0.01 0.47
No  1.56 (1.04-2.35) 1.58 (1.05-2.39) 1.94 (1.30-2.89) 2.14 (1.44-3.19) <0.01 0.47
Diabetes        
Yes 1 0.86 (0.50-1.47) 1.12 (0.68-1.84) 1.28 (0.80-2.04) 1.56 (1.00-2.42) <0.01 0.77
No 1 1.21 (0.96-1.53) 1.19 (0.94-1.51) 1.35 (1.07-1.70) 1.51 (1.20-1.90) <0.01 0.77
BMI, kg/m2        
<25 1 1.35 (0.99-1.83) 1.28 (0.94-1.76) 1.45 (1.07-1.98) 1.60 (1.18-2.19) <0.01 0.84
≥25 1 0.97 (0.72-1.31) 1.06 (0.79-1.42) 1.20 (0.91-1.59) 1.42 (1.08-1.86) <0.01 0.84
Current smoking        
Yes 1 1.14 (0.79-1.65) 1.42 (0.99-2.01) 1.38 (0.98-1.96) 1.37 (0.97-1.94) 0.05 0.12
No 1 1.28 (0.97-1.69) 1.08 (0.81-1.44) 1.41 (1.07-1.86) 1.70 (1.30-2.23) <0.01 0.12
*. Adjusted potential confounders included age, sex, body mass index, hypertension, diabetes, triglycerides, high-density lipoprotein cholesterol, smoking status, drinking
status, physical activity status; stratified by hospitals
doi: 10.1371/journal.pone.0074634.t004
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is related to atherosclerosis. Thus, it is reasonable that there is
a positive association between serum non-HDLC concentration
and the risk of ischemic stroke in Chinese adults.
We also analyzed the relationship between the serum non-
HDLC level and occurrence of hemorrhage stroke subtype. Our
study reported a higher proportion of hemorrhagic stroke than
those reported in Western countries, which is consistent with
some previous studies conducted in China
where the proportion of hemorrhagic strokes was reported to
be 17.1% to 55.4% [26,27], higher than the western
populations (6.5% to 19.6%) [28]. The difference might be due
to the uncontrolled hypertension and higher prevalence of
smoking in China. We did not find significant relationship
between the serum non-HDLC level and the risk of
intracerebral hemorrhage or subarachnoid hemorrhage.
Previous reports about the association between the risk of
hemorrhagic stroke and cholesterol have focused on LDL
cholesterol and HDLC, but not non-HDLC, and their
conclusions were inconsistent. Most of these studies
demonstrated an association between low serum cholesterol
levels and the risk of hemorrhagic stroke, such as the ARIC-
CHS study [29] and the study by Cui et al [30]. However, in the
Korean Medical Insurance Corporation Study, low serum
cholesterol concentration did not increase the risk of
intracerebral hemorrhage [31]. With respect to non-HDLC, the
data describing the relationship between serum non-HDLC
level and the risk of hemorrhagic stroke are also controversial.
The JALS-ECC study indicated that the risk of hemorrhagic
stroke was not associated with serum non-HDLC level [10]. In
contrast, Ren et al reported that compared to the lowest
quintile group of non-HDLC, the risk of hemorrhagic stroke was
not markedly declined in the top quintile group [11], which was
consistent with our results. We were aware that compared to
ischemic stroke the numbers of intracerebral and subarachnoid
hemorrhage cases in this study were small, which is insufficient
to determine if there is a positive, negative or no association
between these stroke subtypes and non-HDL-C. The wide CIs
are consistent with all three possibilities. Therefore, future
study with larger hemorrhagic case number is needed to further
address this question.
Compared to previous reports, our study demonstrated
unique strengths and advantages. First, our data were
generated from a prospective cohort study with a very large
sample size (~ 1000,000 adults). Of importance, the Chinese
adult participants enrolled in our study showed a similar
baseline participants’ distribution as other epidemiological
studies in China [32,33]. Additionally, individuals who took lipid-
lowering medications were excluded from our study, making
the serum lipid level in our cohort participants highly close to
the normal population. With such large sample size and several
years of accurate follow-up, we were able to identify that the
serum non-HDLC level is an independent risk factor for stroke
and associated with increased incidences of total and ischemic
stroke. A few limitations of this study need to be acknowledged.
Firstly, it is possible that the association between serum non-
HDLC concentration and the risk for stroke is underestimated
because of the single measurement of serum non-HDLC level
at the baseline survey. Secondly, we should be careful to
translate our observation to general Chinese population due to
selection of participants in our study. The participants enrolled
in our study were mainly the mining employees of the Kailuan
group with a significantly higher ratio of male to female (80% to
20%) than the general Chinese population. Thirdly, we
analyzed the effect of potential confounding factors on the
association between serum non-HDLC levels and stroke
incidences. Unfortunately one of the two groups for each risk
factor examined has very wide CIs possibly due to small
numbers. Therefore, we are aware that this component of the
analyses is underpowered and might be only suggestive of,
rather than directly demonstrating, no interactions or effect
modification of these confounding factors. Lastly, the reported
association between non-HDLC and risk of stroke may be
further underestimated due to possible effect of silent
infarction, which was not assessed in our study. Silent
infarction has an estimated prevalence of 6%-28% and the
prevalence is higher in elder generations [34,35].
Conclusions
The present large prospective cohort study based on a
Chinese community population showed that the serum non-
HDLC is an impendent risk factor for stroke and its certain
subtypes, and that high serum non-HDLC concentration is
associated with the increased risk for total stroke and ischemic
stroke, but not for intracerebral hemorrhage and subarachnoid
hemorrhage. As a non-expensive and easily tested biomarker,
non-HDLC may represent an important alternative screening
marker for primary prevention of ischemic stroke among
Chinese adults.
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